Stefan Coassin - Genetic Mutations

Author Information

Stefan Coassin is affiliated with the Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria. His research primarily focuses on genetic epidemiology and cardiovascular diseases.

Research Contributions

Stefan Coassin has made significant contributions to the field of genetic epidemiology, particularly in understanding the genetic determinants of cardiovascular diseases. His work involves genome-wide characterization of hyperlipoprotein(a)emia and the role of LPA variants in cardiovascular risk. Notably, he has explored the impact of LPA KIV-2 variants on lipoprotein(a) concentrations and their protective effects against coronary artery disease. Additionally, his research has delved into the interplay between lipoprotein(a) and SARS-CoV-2 infections, and the influence of PCSK9 inhibitors on lipoprotein(a) reduction.

Aliases

Stefan Coassin is also known as S. Coassin.

Publication and Citation Metrics

Metric	Value
Total Citations	4068
h-index	30
Total Publications	95

Publications:

Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk

DOI: 10.1161/CIRCGEN.121.003489

Year: 2022

Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease.

DOI: 10.1016/j.jacc.2021.05.037

Year: 2021

The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors.

DOI: 10.1093/cvr/cvab247

Year: 2021

Cis-epistasis at the LPA locus and risk of cardiovascular diseases

DOI: 10.1093/cvr/cvab136

Year: 2021

Genome-wide characterization of a highly penetrant form of hyperlipoprotein(a)emia causatively associated with genetically elevated cardiovascular risk

DOI: 10.1016/j.atherosclerosis.2021.06.338

Year: 2021

Lysis reagents, cell numbers, and calculation method influence high-throughput measurement of HDL-mediated cholesterol efflux capacity

DOI: 10.1016/j.jlr.2021.100125

Year: 2021

Lipoprotein(a) and SARS‐CoV‐2 infections: susceptibility to infections, ischemic heart disease and thromboembolic events

DOI: 10.1111/joim.13338

Year: 2021

In transition to the next generation reference materials and reference measurement procedures for apolipoprotein standardization

DOI: 10.1016/j.atherosclerosis.2021.06.618

Year: 2021

When the genome bluffs: a tandem duplication event during generation of a novel Agmo knockout mouse model fools routine genotyping

DOI: 10.1186/s13578-021-00566-9

Year: 2021

Highly frequent variants hidden in the KIV-2 region of LPA regulate lipoprotein(a) concentrations and lower coronary artery disease risk

DOI: 10.1016/j.atherosclerosis.2021.06.022

Year: 2021

How is Third Generation Sequencing Used in Research and Medicine?

Why is Hemoglobin Electrophoresis Important?

What are Targeted Therapies?

How Does Genetic Testing Help in Managing Cystic Fibrosis?

What Protective Measures Can Be Taken?

What Are the Applications of Sanger Sequencing in Genetic Research?

What Are the Ethical Considerations for CRISPR Technology?

Are There Any Treatments Specifically Targeting BRCA1 and BRCA2 Mutations?

What is Genome Editing?

What Measures Can Be Taken to Mitigate the Risks?

Partnered Content Networks

Relevant Topics